Heartland Group (NZX:HGH) reports NPAT of NZ$87 million in its FY21 annual report


  • Heartland achieved a strong FY21, posting a 20% rise in NPAT.
  • The Group expects its NPAT to be between NZ$93 million and NZ$96 million.

Heartland Group Holdings Limited (NZX:HGHASX:HGH) released its annual report on Monday. Heartland countered well to the economic effects that came due to COVID-19. The Group posted subdued growth in H1 of FY21 amid COVID-19, but higher growth was seen in HGH’s core lending portfolios in H2 FY21. This helped Heartland in posting a strong FY21 result.

The Group achieved an NPAT of NZ$87 million for FY21, up 20% on FY20 and gross finance receivables grew to NZ$5 billion, up 8% on FY20. Heartland also made considerable progress on strategic targets in digitalisation during the year.

Image source: © 2021 Kalkine Media New Zealand Ltd

Image Description: People discussing company financials

The Group provided access to the NZ government’s Business Finance Guarantee Scheme to over 150 customers and lent over NZ$188 million via its Heartland Extend product for customers needing flexibility with repayments.

RELATED ARTICLE: Do these 5 NZX financial stocks have healthy YTD returns?

HGH paid a final dividend of 7cps on 15 September. The total dividend for the year stood at 11cps. The Group’s Board intends to hire Geoff Summerhayes and Kate Mitchell as directors effective 1 October 2021.

On 27 September, HGH was trading down by 1.31% at NZ$2.26, at the time of writing.


Heartland expects its NPAT to be in the range of NZ$93 million and NZ$96 million for FY22 amid uncertainties associated to COVID-19. The Group also remains positive to deliver on its growth and profitability.



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK